Sparc encoding polynucleotide as a cancer therapy sensitizer
CA 2802143 C · Owner: Dana-Farber Cancer Institute · Inventors: Tai, Isabella T.; Chen, Lan Bo
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to compositions and methods for sensitizing cancer therapy. The invention provides such compositions comprising a SPARC family polypeptide or polynucleotide as well as recombinant cells containing a SPARC family polypeptide or polynucleotide. The compositions and methods of the invention are useful in in vitro study of cancer therapy resistance as well as ex vivo and in vivo therapy of cancer.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 14, 2004 and granted June 19, 2018. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 14, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 14, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.